BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230509
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T062357
CREATED:20230227T131842Z
LAST-MODIFIED:20230227T131842Z
UID:36691-1683590400-1683849599@www.pharmajournalist.com
SUMMARY:4th STING & TLR Targeting Therapies Summit
DESCRIPTION:Facilitating key conversations needed to drive forward the development of safe and effective innate stimulating immunotherapies\, the 4th STING & TLR Targeting Therapies Summit will take place\, for the first time ever in person\, in Boston on May 9-11\, 2023. \nView the official program here. \nExplore innate agonists from discovery to translation with the leaders in the space and gain insight into clinical updates\, unpack what went wrong with some failures like ADU-S100 and address critical challenges including driving down toxicity\, preclinical model selection and choosing appropriate delivery mechanisms. \nHere are some exciting highlights you cannot miss including: \n\nReviewing the clinical landscape in the past year\, key updates in innate agonists that have moved through the clinic\, and identifying the root of failed trials through integral discussions led by Beacon Targeted Therapies\, Tempest Therapeutics\, and #Indaptus Therapeutics\nAssessing the best innate agonist delivery approaches\, from data on antibody-conjugated STING agonists with Takeda Oncologyand ImmuneSensor to unpacking 7&8 Biopharma’s IV delivery to extracellular vesicle approaches with Codiak Bio \nRevisiting cancer vaccines and navigating their development with post-COVID vaccine considerations; with Elicio Therapeuticsand UT Southwestern Medicine\, exploring the use of STING / TLR adjuvants to deliver on this promising therapeutic\nVenturing beyond oncology to learn from drug developers utilizing STING & TLR agonists to treat infectious diseases and adding these potent innate activators to our arsenal to be better equipped for the next pandemic\n\nView the complete agenda and speaker line-up. \nBeing the only meeting dedicated to driving forward the development of innate immune agonists\, we encourage you to take this exciting opportunity to unite and leverage the industry’s cumulative knowledge and experience to have meaningful conversations that will translate STING & TLR agonists into effective and reliable treatment options.
URL:https://www.pharmajournalist.com/event/4th-sting-tlr-targeting-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T062357
CREATED:20230323T113857Z
LAST-MODIFIED:20230323T113857Z
UID:36881-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients Conference 2023
DESCRIPTION:The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027\, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs\, along with the increase in associated toxicities\, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. \nOur 2023 conference brings insights from leading pharmaceutical companies on how to improve hazard identification\, integrate advanced containment controls and mitigate the risk of manufacturing HPAPI. Featuring leading speakers including directors\, engineers\, and experts in validation requirements this conference provides an extensive look at how you can futureproof your pharmaceutical manufacturing facilities. \nThis two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS\, Occupational Hygiene\, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event\, including key regulatory updates\, and leading case studies from leading pharmaceutical and biotechnology companies. \nBenefits of Attending the HPAPI Conference: \n\nLEARN how to ensure advanced therapeutic manufacturing is safe for workers and patients\nINCREASE the effectiveness of your engineering containment controls by improving harmony between the worker engineer and toxicologist to ensures cost-effective design choices\nUNCOVER the best practises & opportunities for pharmaceutical companies to work alongside CMOs to effectively and efficiently scale-up HPAPI manufacturing\nREVIEW case studies on the implementation of risk-based hazard identification strategies from leading pharmaceutical companies including AstraZeneca\, CSL Behring and Merck\n\nDISCOVER future trends in containment and control technologies to future-proof your HPAPI manufacturing plant to maximsie operator safety \nTo know more visit: www.highlypotentapi.com/PharmaJournalistEL
URL:https://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-conference-2023/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T062357
CREATED:20230323T114213Z
LAST-MODIFIED:20230323T114213Z
UID:36887-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:5th Annual Injectable Drug Delivery Conference
DESCRIPTION:Exploring Injectable Drug Formulations and Device Development \nSponsors: Victrex \nExhibitors: PHC Group  \nAs Part of Europe’s leading Injectable conference series\, the 5th annual Injectable Drug Delivery conference will assess innovations in drug product formulation and biologics\, new technologies in device design\, along with the latest regulatory considerations for optimal drug delivery. \n \nWith increasing demand for vaccines\, insulin\, and many other modern medicines administered via the injectable route\, there is significant growth projected in the biologics market\, particularly the injectable drug delivery and prefilled syringe market which is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. It is due to this rising demand and increased growth that the industry must come together to discuss and critically evaluate the next generation of injectable drug delivery. \nAt this year’s event we will highlight the most recent innovations within the industry\, with regard to injectable device design and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. In silico modelling will be addressed as we continue to see a move towards AI utilisation\, alongside key CMC concerns and usability of injectable devices in digital health. The conference will also highlight the significance of sustainability within the industry\, whilst providing regulatory insight on the changes that have occurred and are forecast in the coming years. \nBenefits of attending: \n\nExplore the latest trends within the Injectable drug delivery field\, with new insights into in-silico modelling\nExpand on current knowledge of device design\, with special considerations for primary and secondary packaging\nExamine injectable drug formulation strategies\, including novel formulation methodologies\nLearn how to advance the injectable drug delivery landscape through a review of current regulatory compliance\nRealise how Chemical Manufacturing and Control can further expand the industry through digitalisation strategies\n\nTo know more visit: http://www.injectable-drug-delivery.com/PharmaJournalist-EI
URL:https://www.pharmajournalist.com/event/5th-annual-injectable-drug-delivery-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
END:VCALENDAR